Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-42491293 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | \[11C\] JNJ-42491293 + JNJ-40411813 Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan,\[11C\] JNJ-42491293 + JNJ-40411813 Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection. Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain,\[11C\] JNJ-42491293 Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.,\[11C\] JNJ-42491293 Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection have a 90 minute PET scan and have arterial and venous blood sampling. |
| Name | Type | Description |
|---|---|---|
| [11C] JNJ-42491293 | DRUG | Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling. |
| [11C] JNJ-42491293 + JNJ-40411813 | DRUG | Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan |
Inclusion Criteria: * Body mass index (BMI) between 18 and 30 kg/m2, inclusive (BMI = weight/height2) * Nonsmokers (at least 3 months before screening) * Healthy on the basis of results from physical examination, vital signs, and 12-lead ECG, clinical laboratory tests performed at screening as dete...
JNJ-42491293 is an investigational small molecule being studied as a possible PET ligand for the mGlu2 receptor. It is in Phase 1 clinical development by Johnson & Johnson. The drug is being evaluated in healthy adult volunteers to assess its potential as an imaging agent.
JNJ-42491293 targets the mGlu2 receptor, as indicated by its development as a possible PET ligand for this receptor. The drug is designed to bind to mGlu2 receptors, potentially enabling visualization of these receptors through positron emission tomography imaging.
JNJ-42491293 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research on this investigational small molecule.
JNJ-42491293 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug remains in early-stage clinical research.
JNJ-42491293 has one completed Phase 1 clinical trial, identified as NCT01359852. This study, titled "A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers," enrolled 20 healthy male participants aged 18 years and older.
Yes, JNJ-42491293 is the same as [11C]JNJ-42491293. The [11C] designation indicates the compound is labeled with carbon-11, a radioactive isotope used in positron emission tomography imaging. The clinical trial NCT01359852 specifically studied the [11C]-labeled form of JNJ-42491293.